Therapeutic mTOR inhibition in autosomal dominant polycystic kidney disease: What is the appropriate serum level?

American Journal of Transplantation

Volumn 10, Issue 7, 2010, Pages 1710-1715

  Canaud, G ^a,b   Knebelmann, B ^a,b   Harris, P C ^c   Vrtovsnik, F ^d   Correas, J M ^a   Pallet, N ^a,b   Heyer, C M ^c   Letavernier, E ^d   Bienaime F ^a,b   Thervet, E ^a,b   Martinez, F ^a,b   Terzi, F ^a,b   Legendre, C ^a,b  

^a HÔPITAL NECKER ENFANTS MALADES   (France)

^b UNIVERSITÉ PARIS DESCARTES   (France)

^c MAYO CLINIC   (United States)

^d BICHAT HOSPITAL   (France)

Author keywords

Disease transmission; DNA sequencing; donor risk; mTOR inhibitor; peripheral blood; polycystic kidney disease; renal allograft biopsies; renal medicine; sirolimus

Indexed keywords

MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; POLYCYSTIN 1; RAPAMYCIN; TACROLIMUS; TARGET OF RAPAMYCIN KINASE;

ADULT; ARTICLE; AUTOSOMAL DOMINANT INHERITANCE; AUTOSOMAL DOMINANT POLYCYSTIC KIDNEY DISEASE; CASE REPORT; DNA SEQUENCE; DRUG BLOOD LEVEL; ENZYME ACTIVATION; ENZYME ACTIVITY; ENZYME INHIBITION; FEMALE; GENE MUTATION; GRAFT FAILURE; GRAFT RECIPIENT; HUMAN; KIDNEY FUNCTION; KIDNEY POLYCYSTIC DISEASE; KIDNEY TRANSPLANTATION; MALE; PRIORITY JOURNAL; SIGNAL TRANSDUCTION;

EID: 77954056903     PISSN: 16006135     EISSN: 16006143     Source Type: Journal    
DOI: 10.1111/j.1600-6143.2010.03152.x     Document Type: Article

References (29)

1. Wilson PD. Polycystic kidney disease. N Engl J Med 2004 350 : 151 164.
2. Rossetti S, Consugar MB, Chapman AB et al. Comprehensive molecular diagnostics in autosomal dominant polycystic kidney disease. J Am Soc Nephrol 2007 18 : 2143 2160. (Pubitemid 47041080)
3. Torres VE, Harris PC. Autosomal dominant polycystic kidney disease: The last 3 years. Kidney Int 2009 76 : 149 168.
4. Harris PC, Torres VE. Polycystic kidney disease. Annu Rev Med 2009 60 : 321 337.
5. Edelstein CL. Mammalian target of rapamycin and caspase inhibitors in polycystic kidney disease. Clin J Am Soc Nephrol 2008 3 : 1219 1226.
6. Shillingford JM, Murcia NS, Larson CH et al. The mTOR pathway is regulated by polycystin-1, and its inhibition reverses renal cystogenesis in polycystic kidney disease. Proc Natl Acad Sci USA 2006 103 : 5466 5471.
7. Tao Y, Kim J, Schrier RW, Edelstein CL. Rapamycin markedly slows disease progression in a rat model of polycystic kidney disease. J Am Soc Nephrol 2005 16 : 46 51.
8. Qian Q, Du H, King BF et al. Sirolimus reduces polycystic liver volume in ADPKD patients. J Am Soc Nephrol 2008 19 : 631 638.
9. Grantham JJ, Torres VE, Chapman AB et al. Volume progression in polycystic kidney disease. N Engl J Med 2006 354 : 2122 2130.
10. Chapman AB, Guay-Woodford LM, Grantham JJ et al. Renal structure in early autosomal-dominant polycystic kidney disease (ADPKD): The consortium for radiologic imaging studies of polycystic kidney disease (CRISP) cohort. Kidney Int 2003 64 : 1035 1045.
11. Bae KT, Commean PK, Lee J. Volumetric measurement of renal cysts and parenchyma using MRI: Phantoms and patients with polycystic kidney disease. J Comput Assist Tomogr 2000 24 : 614 619.
12. Stevens LA, Levey AS. Measured GFR as a confirmatory test for estimated GFR. J Am Soc Nephrol 2009 20 : 2305 2313.
13. Boulay A, Zumstein-Mecker S, Stephan C et al. Antitumor efficacy of intermittent treatment schedules with the rapamycin derivative RAD001 correlates with prolonged inactivation of ribosomal protein S6 kinase 1 in peripheral blood mononuclear cells. Cancer Res 2004 64 : 252 261.
14. Hartmann B, Schmid G, Graeb C et al. Biochemical monitoring of mTOR inhibitor-based immunosuppression following kidney transplantation: A novel approach for tailored immunosuppressive therapy. Kidney Int 2005 68 : 2593 2598.
15. Wullschleger S, Loewith R, Hall MN. TOR signaling in growth and metabolism. Cell 2006 124 : 471 484.
16. Spees EK, Orlowski JP, Fitting KM, Temple DM, Reynolds CP. Successful use of cadaver kidneys from diabetic donors for transplantation. Transplant Proc 1990 22 : 378 379.
17. Mancini G, Comparini L, Salvadori M. Transplant of a polycystic kidney because of organ shortage. Transplant Proc 1990 22 : 376.
18. Siegal B. The polycystic kidney donor. Transplantation 1992 54 : 1131.
19. Shan YS, Lee PC, Sy ED, Hung CJ, Lin YJ. Polycystic kidney patient as a cadaveric donor: Is it appropriate? Nephrol Dial Transplant 2001 16 : 410 411.
20. Powell CR, Tata S, Govani MV, Chien GW, Orvieto MA, Shalhav AL. Transplantation of a cadaveric polycystic kidney in a patient with autosomal dominant polycystic kidney disease: Long-term outcome. Transplant Proc 2004 36 : 1288 1292.
21. Howard RJ, Reed AI, Van Der Werf WJ, Silkensen JA, Patton PR, Scornik JC. Development of polycystic disease in a kidney 10 years after transplantation. Transplantation 1999 68 : 1620.
22. Rossetti S, Kubly VJ, Consugar MB et al. Incompletely penetrant PKD1 alleles suggest a role for gene dosage in cyst initiation in polycystic kidney disease. Kidney Int 2009 75 : 848 855.
23. Piontek K, Menezes LF, Garcia-Gonzalez MA, Huso DL, Germino GG. A critical developmental switch defines the kinetics of kidney cyst formation after loss of PKD1. Nat Med 2007 13 : 1490 1495.
24. Verdeguer F, Le Corre S, Fischer E et al. A mitotic transcriptional switch in polycystic kidney disease. Nat Med 2010 16 : 106 110.
25. Wahl PR, Serra AL, Le Hir M, Molle KD, Hall MN, Wuthrich RP. Inhibition of mTOR with sirolimus slows disease progression in Han: SPRD rats with autosomal dominant polycystic kidney disease (ADPKD). Nephrol Dial Transplant 2006 21 : 598 604.
26. Ekberg H, Tedesco-Silva H, Demirbas A et al. Reduced exposure to calcineurin inhibitors in renal transplantation. N Engl J Med 2007 357 : 2562 2575.
27. Russ G, Segoloni G, Oberbauer R et al. Superior outcomes in renal transplantation after early cyclosporine withdrawal and sirolimus maintenance therapy, regardless of baseline renal function. Transplantation 2005 80 : 1204 1211.
28. Letavernier E, Bruneval P, Mandet C et al. High sirolimus levels may induce focal segmental glomerulosclerosis de novo. Clin J Am Soc Nephrol 2007 2 : 326 333.
29. Wang T, Li BY, Danielson PD et al. The immunophilin FKBP12 functions as a common inhibitor of the TGF beta family type I receptors. Cell 1996 86 : 435 444.